Abstract
Background: Optimal management of locally advanced non-small cell lung cancer (NSCLC) lacks consensus. A retrospective analysis of patient data entered in the Veterans Affairs Central Cancer Registry was conducted to evaluate these issues. Patients and Methods: Data of patients with cT1-4, cN2, and cM0 NSCLC diagnosed in the VA Health System between 1995 and 2003 were evaluated. Age, sex, race, smoking history, TNM stage, treatment, and overall survival were abstracted. Survival was compared using multivariate Cox proportional hazards regression analysis. Results: Of the 7328 patients analyzed, 7218 (98.5%) were male, 6061 (82.7%) were white, and 321 (4.4%) were never smokers. The treatment received included: none, 23.8%; chemotherapy alone, 14.3%; radiation alone, 23%; and chemoradiation (sequential or concurrent), 31.4%. Only 7.5% of patients had a surgical resection, with or without multimodality therapy. The median survival (months) of these patient groups were: surgery, 19.3; chemoradiation, 13; chemotherapy alone, 9.2; radiation alone, 7.3; and no treatment, 4 (P <0.0001). African Americans had a significantly decreased risk of mortality compared with whites (hazard ratio 0.92; 95% confidence interval, 0.87-0.98). Conclusions: Inclusion of surgical resection as a treatment modality was associated with a better overall survival. Also, African Americans appeared to do better than whites. These hypothesis-generating findings should be useful in the ongoing pursuit of better treatment strategies for locally advanced NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 142-146 |
| Number of pages | 5 |
| Journal | American Journal of Clinical Oncology |
| Volume | 39 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
- Medicine(all)
Cite this
Effect of surgical intervention on survival of patients with clinical N2 non-small cell lung cancer : A veterans' affairs central cancer registry (VACCR) database analysis. / Ganti, Apar K.; Gonsalves, Wilson; Loberiza, Fausto R.; Aldoss, Ibrahim; Batra, Rishi; Silberstein, Peter T.; Subbiah, Shanmuga P.; Kessinger, Anne.
In: American Journal of Clinical Oncology, Vol. 39, No. 2, 2016, p. 142-146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of surgical intervention on survival of patients with clinical N2 non-small cell lung cancer
T2 - A veterans' affairs central cancer registry (VACCR) database analysis
AU - Ganti, Apar K.
AU - Gonsalves, Wilson
AU - Loberiza, Fausto R.
AU - Aldoss, Ibrahim
AU - Batra, Rishi
AU - Silberstein, Peter T.
AU - Subbiah, Shanmuga P.
AU - Kessinger, Anne
PY - 2016
Y1 - 2016
N2 - Background: Optimal management of locally advanced non-small cell lung cancer (NSCLC) lacks consensus. A retrospective analysis of patient data entered in the Veterans Affairs Central Cancer Registry was conducted to evaluate these issues. Patients and Methods: Data of patients with cT1-4, cN2, and cM0 NSCLC diagnosed in the VA Health System between 1995 and 2003 were evaluated. Age, sex, race, smoking history, TNM stage, treatment, and overall survival were abstracted. Survival was compared using multivariate Cox proportional hazards regression analysis. Results: Of the 7328 patients analyzed, 7218 (98.5%) were male, 6061 (82.7%) were white, and 321 (4.4%) were never smokers. The treatment received included: none, 23.8%; chemotherapy alone, 14.3%; radiation alone, 23%; and chemoradiation (sequential or concurrent), 31.4%. Only 7.5% of patients had a surgical resection, with or without multimodality therapy. The median survival (months) of these patient groups were: surgery, 19.3; chemoradiation, 13; chemotherapy alone, 9.2; radiation alone, 7.3; and no treatment, 4 (P <0.0001). African Americans had a significantly decreased risk of mortality compared with whites (hazard ratio 0.92; 95% confidence interval, 0.87-0.98). Conclusions: Inclusion of surgical resection as a treatment modality was associated with a better overall survival. Also, African Americans appeared to do better than whites. These hypothesis-generating findings should be useful in the ongoing pursuit of better treatment strategies for locally advanced NSCLC.
AB - Background: Optimal management of locally advanced non-small cell lung cancer (NSCLC) lacks consensus. A retrospective analysis of patient data entered in the Veterans Affairs Central Cancer Registry was conducted to evaluate these issues. Patients and Methods: Data of patients with cT1-4, cN2, and cM0 NSCLC diagnosed in the VA Health System between 1995 and 2003 were evaluated. Age, sex, race, smoking history, TNM stage, treatment, and overall survival were abstracted. Survival was compared using multivariate Cox proportional hazards regression analysis. Results: Of the 7328 patients analyzed, 7218 (98.5%) were male, 6061 (82.7%) were white, and 321 (4.4%) were never smokers. The treatment received included: none, 23.8%; chemotherapy alone, 14.3%; radiation alone, 23%; and chemoradiation (sequential or concurrent), 31.4%. Only 7.5% of patients had a surgical resection, with or without multimodality therapy. The median survival (months) of these patient groups were: surgery, 19.3; chemoradiation, 13; chemotherapy alone, 9.2; radiation alone, 7.3; and no treatment, 4 (P <0.0001). African Americans had a significantly decreased risk of mortality compared with whites (hazard ratio 0.92; 95% confidence interval, 0.87-0.98). Conclusions: Inclusion of surgical resection as a treatment modality was associated with a better overall survival. Also, African Americans appeared to do better than whites. These hypothesis-generating findings should be useful in the ongoing pursuit of better treatment strategies for locally advanced NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=84893184959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893184959&partnerID=8YFLogxK
U2 - 10.1097/COC.0000000000000040
DO - 10.1097/COC.0000000000000040
M3 - Article
C2 - 24487419
AN - SCOPUS:84893184959
VL - 39
SP - 142
EP - 146
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 2
ER -